• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Thermo Fisher expands gene therapy portfolio

July 8, 2021 By Sean Whooley

Thermo Fisher

Thermo Fisher Scientific (NYSE:TMO) announced a new set of solutions to support adeno-associated viral (AAV) manufacturing. AAV, a non-pathogenic virus capable of infecting cells at various stages of growth, has become a preferred “viral vector” for delivering gene therapies, although the scalability of AAV remains a challenge. According to a news release, Thermo Fisher designed […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals Tagged With: thermofisherscientific

Thermo Fisher Scientific expands corporate leadership team

July 7, 2021 By Sean Whooley

Thermo Fisher

Thermo Fisher Scientific (NYSE:TMO) announced today that it appointed Dr. Alan Sachs to chief medical officer and Karen E. Nelson to chief scientific officer. Sachs served as Waltham, Mass.-based Thermo Fisher’s CSO since 2016 and will be succeeded by Nelson as he assumes the newly established CMO position at the company. Both will join the […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Personnel, Personnel Moves, thermofisherscientific

Fresenius Kabi launches Simplist fentanyl citrate injection

July 6, 2021 By Sean Whooley

Fentanyl citrate simplist fresenius kabi

Fresenius Kabi announced today that it initiated the U.S. introduction of a fentanyl citrate injection in the Simplist pre-filled syringe. Lake Zurich, Ill.-based Fresenius Kabi’s proprietary Simplist ready-to-administer prefilled syringe offers the fentanyl citrate injection at 50 mcg per 1 mL in an effort to reduce waste and diversion while ensuring the safe delivery of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management Tagged With: freseniuskabi

DarioHealth touts data for diabetes management platform

July 1, 2021 By Sean Whooley

DarioHealth

DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results —presented at the American Diabetes Association (ADA) 81st […]

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring Tagged With: dariohealth

Teva initiates U.S. recall of Topotecan metastatic ovarian cancer injection treatment

July 1, 2021 By Sean Whooley

Teva

Teva Pharmaceuticals (NYSE:TEVA) initiated a voluntary recall of a lot of its Topotecan injection 4mg/4mL (1mg/mL) in the U.S. The voluntary recall came as a result of a complaint received from a pharmacy after a single glass particle was observed inside one vial. Following further examination of the complaint sample, two other particulates were found […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Immunotherapy, Oncology, Recalls Tagged With: FDA, Teva, Teva Pharmaceuticals

PharmaJet begins enrollment for needle-free COVID-19 vaccine trial

June 30, 2021 By Sean Whooley

PharmaJet

PharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia. Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. According to a news release, PharmaJet’s system was chosen […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

United Therapeutics touts study results for inhaled Tyvaso treatment

June 30, 2021 By Sean Whooley

Tyvaso United Therapeutics

United Therapeutics (NSDQ:UTHR) today announced positive results from an analysis of forced vital capacity (FVC) change with its Tyvaso treatment. Research Triangle Park, N.C.–based United Therapeutics developed Tyvaso (treprostinil) as an inhalation solution for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA approved the treatment in April 2020. The posthoc analysis of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: United Therapeutics

Giiant Pharma extends seed round with $1.25M

June 30, 2021 By Sean Whooley

GIIANT Pharma_Logo_RGB_noname

Giiant Pharma announced today that it added $1.25 million to its seed financing round to ensure reaching clinical proof-of-concept for its Precision Delivery technology platform. Montreal-based Giiant’s $750,000 in funding from AQC Capital, plus $500,000 from CQDM, adds to the seed round closed last month to bring the company’s total funding to nearly $15 million. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: Giiant Pharma

Charles River Laboratories completes $292.5M Vigene acquisition

June 29, 2021 By Sean Whooley

charles river laboratories

Charles River Laboratories (NYSE:CRL) announced that it completed a $292.5 million acquisition of Vigene Biosciences. Rockville, Md.-based Vigene, a gene therapy contract development and manufacturing organization (CDMO), develops viral vector-based gene delivery systems, with a primary area of expertise in CGMP viral vector manufacturing for gene therapies and gene-modified cell therapies. According to a news […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Charles River Laboratories, Vigene Biosciences

Boston Children’s Hospital, ElevateBio enter 5-year cell, gene therapy collaboration

June 29, 2021 By Sean Whooley

Elevatebio-logo

Boston Children’s Hospital announced today that it partnered with ElevateBio for a five-year cell and gene therapy advancement program. The collaborative agreement will seek to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities. Cambridge, Ma.-based ElevateBio will offer Boston Children’s researchers access […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Oncology Tagged With: Boston Children's Hospital, ElevateBio

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 135
  • Page 136
  • Page 137
  • Page 138
  • Page 139
  • Interim pages omitted …
  • Page 174
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS